{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:06:38Z","timestamp":1772168798125,"version":"3.50.1"},"reference-count":13,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory \u00b1 allergic theme.\u00a0 Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to impede mast cell mediator production and action and, when necessary, inhibition of proliferation. Some tyrosine kinase inhibitors (TKIs) have been used successfully in uncommon cases of systemic mastocytosis not bearing that disease\u2019s usual imatinib-resistant KIT\n                    <ns4:sup>D816V<\/ns4:sup>\n                    mutation. Recently, sunitinib, a multi-targeted TKI, had been successful in a case of systemic mast cell activation syndrome. In addition, most allergy is principally a mast cell activation phenomenon, and sunitinib has been shown helpful in controlling a murine model of oral allergy syndrome. Here, we present the first use of sunitinib in systemic mastocytosis.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.13343.1","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T05:30:04Z","timestamp":1514439004000},"page":"2182","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Treatment of systemic mastocytosis with sunitinib"],"prefix":"10.12688","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-2749","authenticated-orcid":false,"given":"Gerhard J.","family":"Molderings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence B.","family":"Afrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-J\u00f6rg","family":"Hertfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Brettner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"197-205","DOI":"10.1111\/j.1365-2567.2012.03627.x","article-title":"Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.","volume":"137","author":"B Haenisch","year":"2012","journal-title":"Immunology."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"190-201","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options.","volume":"48","author":"L Afrin","year":"2016","journal-title":"Ann Med."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"86-97","DOI":"10.1016\/j.trsl.2016.01.001","article-title":"Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features.","volume":"174","author":"G Molderings","year":"2016","journal-title":"Transl Res."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"345-351","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.","volume":"107","author":"H Droogendijk","year":"2006","journal-title":"Cancer."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"2530-2541","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis.","volume":"374","author":"J Gotlib","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"3906-3915","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.","volume":"14","author":"S Verstovsek","year":"2008","journal-title":"Clin Cancer Res."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1481-1484","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.","volume":"33","author":"A Vega-Ruiz","year":"2009","journal-title":"Leuk Res."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"114-122","DOI":"10.1111\/j.1398-9995.2011.02717.x","article-title":"Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice.","volume":"67","author":"K Yamaki","year":"2012","journal-title":"Allergy."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"671-694","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease.","volume":"389","author":"G Molderings","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"595-597","DOI":"10.1111\/ejh.12606","article-title":"Successful treatment of mast cell activation syndrome with sunitinib.","volume":"95","author":"L Afrin","year":"2015","journal-title":"Eur J Haematol."},{"key":"ref-11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv292","article-title":"Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.","volume":"108","author":"B Carlisle","year":"2016","journal-title":"J Natl Cancer Inst."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"987-989","DOI":"10.1160\/TH11-05-0351","article-title":"Bleeding diathesis in patients with mast cell activation disease.","volume":"106","author":"H Seidel","year":"2011","journal-title":"Thromb Haemost."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease.","volume":"10","author":"M Vysniauskaite","year":"2015","journal-title":"PLoS One."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T07:09:49Z","timestamp":1544080189000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":13,"URL":"https:\/\/doi.org\/10.12688\/f1000research.13343.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.14480.r29334","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.14480.r29333","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.14480.r33390","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.14480.r29334","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.14480.r29333","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.14480.r33390","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,28]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.14480.r29333, Michael Huber, Institute of Biochemistry and Molecular Immunology, Medical Faculty, \u00a0RWTH Aachen University, Aachen, Germany, 08 Jan 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1#referee-response-29333","order":0,"name":"referee-response-29333","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.14480.r33390, Leonard Weinstock, Washington University School of Medicine, St. Louis, MO, USA, 10 May 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1#referee-response-33390","order":1,"name":"referee-response-33390","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.14480.r29334, Vicki Ratner, Founder and President Emeritus, Interstitial Cystitis Association of America (ICA), McLean, VA, USA, 14 May 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-2182\/v1#referee-response-29334","order":2,"name":"referee-response-29334","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}